Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues ...

Stocks are set to close out April with major gains even as a war in the Middle East is ongoing, and fears around AI ...

TheFly reported on April 9 that B. Riley Financial increased its price target on NVAX from $16 to $18 while maintaining a Buy ...

The European Commission has approved Moderna’s mCombriax, the first mRNA vaccine to combine protection against influenza and COVID-19 for adults aged 50 and above. The decision follows Phase 3 trial ...

Members of the public who spend a significant amount of time with chickens or other birds are being encouraged to sign up for ...

Moderna MRNA reported that the European Commission (EC) has granted marketing authorization for mCombriax (mRNA-1083), its ...

In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for ...

A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more ...

The biotech sector is having another one of its moments—the kind that sends retail investors scrambling for the sidelines ...

A first-of-its-kind trial has been launched to test a new vaccine for bird flu in humans.Thousands of people in the UK are ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

The Department of Health and Human Services had canceled hundreds of millions of dollars in funding previously committed to ...